世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000033373

うっ血性心不全治療薬市場規模、シェア、動向分析レポート、予測2022-2030

Grand View Research Inc.

Congestive Heart Failure Drugs Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2022 - 2030

発刊日 2022/10

言語英語

体裁PDF/100ページ

ライセンス/価格100ページ

0000033373

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

うっ血性心不全治療薬の市場規模、シェア、動向分析レポート、薬剤クラス別 (ACE 阻害剤、アンギオテンシン 2 受容体遮断薬)、流通経路別、地域別、およびセグメント予測、2022 〜 2030

レポートの概要
世界のうっ血性心不全治療薬の市場規模は、2021 年に 61.5 億ドルと評価され、2022 年から 2030 年までに14.60% のCAGRで拡大すると予想されます。市場は、強力な製品パイプライン、高齢者人口の増加、および医薬品開発のための研究開発の増加によって、成長を遂げています。成長を促進するもう 1 つの主な要因は、肥満、糖尿病、高血圧、慢性肺疾患、腎疾患などの疾患の負担が増大していることです。予測期間中は、ジェネリック医薬品の高い普及率によって、成長が鈍化すると予想されます。うっ血性心不全 (CHF) は、罹患率と死亡率が高く、依然として非常に蔓延している世界的な問題です。Global Health Data Exchange レジストリによると、世界の有病率は約 6,434 万件、米国では 2022 年の有病率は約 550 万件でした。

レポート詳細

目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR's internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Congestive Heart Failure Drugs Market Variables, Trends, and Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 Market Driver Analysis
3.3.1 Rising prevalence of the disease
3.3.2 Growing geriatric population
3.3.3 New product approvals
3.3.4 Strong clinical drugs pipeline
3.4 Market Restraint Analysis
3.4.1 Availability of generic and off-label drugs in market
3.4.2 Poor reimbursement scenarios in developing countries
3.5 Industry Analysis - Porter's
3.6 PESTEL Analysis (Political & Legal, Economic, and Technological)
3.7 Pipeline Analysis, by Phase

Chapter 4 Congestive Heart Failure Drugs Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)
4.1 Congestive Heart Failure Drugs Market: Drug Class Movement Analysis
4.2 ACE Inhibitors
4.2.1 ACE Inhibitors Market, 2018 - 2030 (USD Million)
4.3 Angiotensin 2 Receptor Blockers
4.3.1 Angiotensin 2 Receptor Blockersmarket, 2018 - 2030 (USD Million)
4.4 Beta Blockers
4.4.1 Beta Blockers Market, 2018 - 2030 (USD Million)
4.5 Diuretics
4.5.1 Diuretics Market, 2018 - 2030 (USD Million)
4.6 Aldosterone Antagonists
4.6.1 Aldosterone Antagonists Market, 2018 - 2030 (USD Million)
4.7 Inotropes
4.7.1 Inotropes Market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Congestive Heart Failure Drugs Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
5.1 Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis
5.2 Hospital Pharmacies
5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
5.3 Retail Pharmacies
5.3.1 Retail Pharmacies Market, 2018 - 2030 (USD Million)
5.4 Online Pharmacies
5.4.1 Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6 Congestive Heart Failure Drugs Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2 Europe
6.4.2.1 Europe Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 U.K. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.5 France
6.4.2.5.1 France Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.3 China
6.4.3.3.1 China Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.4 India
6.4.3.4.1 India Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 South Korea Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Australia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5 MEA
6.4.5.1 MEA Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)

Chapter 7 Congestive Heart Failure Drugs Market: Competitive Analysis
7.1 Public Companies
7.1.1 Company Market Position Analysis
7.1.2 Competitive Dashboard Analysis
7.1.3 Strategic Framework
7.2 Private Companies
7.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
7.2.2 Regional Network Map
7.3 Company Profiles
7.3.1 BAYER AG
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 NOVARTIS AG
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 MERCK & CO., INC.
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic Initiatives
7.3.4 ASTRAZENECA
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 BRISTOL-MYERS SQUIBB COMPANY
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 AMGEN INC.
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 BOEHRINGER INGELHEIMINTERNATIONAL GMBH
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 PFIZER, INC.
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 JOHNSON & JOHNSON SERVICES, INC.
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 OTSUKA PHARMACEUTICAL CO., LTD.
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic Initiatives
7.3.11 ELI LILLY AND COMPANY
7.3.11.1 Company Overview
7.3.11.2 Financial Performance
7.3.11.3 Product Benchmarking
7.3.11.4 Strategic Initiatives
7.3.12 NOVO NORDISKA/S
7.3.12.1 Company Overview
7.3.12.2 Financial Performance
7.3.12.3 Product Benchmarking
7.3.12.4 Strategic Initiatives

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Congestive Heart Failure Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 6 Global Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 9 North America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 11 U.S. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Canada Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Canada Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 15 Europe Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 16 Europe Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 U.K. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 U.K. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 France Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 22 France Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Italy Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 24 Italy Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 Spain Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 Spain Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Asia Pacific Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Asia pacific Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Japan Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 31 Japan Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 China Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 33 China Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 India Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 India Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 36 South Korea Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 37 South Korea Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Australia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 Australia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Latin America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 41 Latin America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Latin America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Brazil Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 Brazil Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Mexico Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 46 Mexico Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Argentina Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 Argentina Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Middle East & Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 50 Middle East & Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 52 Saudi Arabia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 South Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 South Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 UAE Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 56 UAE Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Congestive Heart Failure Drugs Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Congestive Heart Failure Drugs Market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Congestive Heart Failure Drugs Market driver impact
Fig. 14 Congestive Heart Failure Drugs Market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter's
Fig. 17 Strategy mapping
Fig. 18 Congestive Heart Failure Drugs Market: Drug Class outlook and key takeaways
Fig. 19 Congestive Heart Failure Drugs Market: Drug Class movement analysis & market share 2021 & 2030
Fig. 20 ACE Inhibitors Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Angiotensin 2 Receptor Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Beta Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Diuretics Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Aldosterone Antagonists Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Inotropes Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Congestive Heart Failure Drugs Market: Distribution Channel outlook and key takeaways
Fig. 28 Congestive Heart Failure Drugs Market: Distribution Channel movement analysis & market share 2021 & 2030
Fig. 29 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Retail and Speciality Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Congestive Heart Failure Drugs Market: Regional outlook and key takeaways
Fig. 33 Regional outlook, 2021 & 2030
Fig. 34 North America
Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S.
Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Canada
Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Europe
Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 U.K.
Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Germany
Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 France
Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Italy
Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain
Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific
Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Japan
Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
Fig. 56 China
Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 India
Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 South Korea
Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Australia
Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Latin America
Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Brazil
Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Mexico
Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Argentina
Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Middle East & Africa
Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 South Africa
Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Saudi Arabia
Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 UAE
Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Market differentiators
Fig. 81 Key company market share analysis, 2021
Fig. 82 Company market position analysis
Fig. 83 Competitive dashboard analysis
Fig. 84 Regional network map

この商品のレポートナンバー

0000033373

TOP